Pharmacyclics Newswire

Pharmacyclics Newswire

Comprehensive Real-Time News Feed for Pharmacyclics.

Results 1 - 20 of 87 in Pharmacyclics

  1. 4 Best Stocks in the Thriving Medical Marijuana IndustryRead the original story w/Photo

    Wednesday May 18 |

    ... sheer momentum of legalized pot. AbbVie has been in the news for its recent acquisitions of cancer companies Pharmacyclics and Stemcentrx and for the imminent patent expiration of arthritis drug Humira . AbbVie's Marinol has already been approved by ...


  2. 5 Stocks We're Watching but Not Buying YetRead the original story w/Photo

    Sunday May 15 | The Motley Fool

    ... from other drugs to insulate itself against future Humira competitors. Last year, it spent $21 billion buying Pharmacyclics to leapfrog to the front of the pack in hematology cancers like chronic lymphocytic leukemia. And AbbVie spent an additional ...


  3. 5 Growth Stocks to Buy in MayRead the original story w/Photo

    Saturday May 14 | The Motley Fool

    ... combined with the company's massive debt load, stemming in large part from its $21 billion acquisition of Pharmacyclics last year. However, the drugmaker's strong first-quarter numbers should help to mute some of these concerns for the time being. ...


  4. Why June Could Be a Big Month for AbbVie InvestorsRead the original story w/Photo

    Thursday May 12 | Fox News

    Emboldened by its successful acquisition of cancer drugmaker Pharmacyclics last year, AbbVie acquired clinical-stage cancer company Stemcentrix in April. The acquisition comes ahead of a key cancer presentation in June that could move the needle for shareholders, so let's take a closer look.


  5. Oxford University Spinout Nabs Record ??16.9 Million in Funding to...Read the original story

    Tuesday May 10 | BioSpace

    ... of Mr Bob Duggan and Dr. Mahkam Zanganeh (former CEO & Chairman and Chief Operating Officer respectively) of Pharmacyclics that was sold last year to AbbVie for US$21 billion. Our other investors include a number of UK and international individuals ...


  6. Janssen Biotech Inc. Release: FDA Expands IMBRUVICA Label To Include...Read the original story

    Sunday May 8 | BioSpace

    ... said , M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC. "In partnership with Pharmacyclics, an AbbVie company, we continue to explore the clinical utility of IMBRUVICA and potential benefit it offers to patients with CLL/SLL ...


  7. AbbVie Release: U.S. FDA Expands IMBRUVICA (Ibrutinib) Label To...Read the original story

    Sunday May 8 | BioSpace

    ... or without the deletion of chromosome 17p (del 17p).1 IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc. The RESONATE-2 trial served as the basis for the March 2016 FDA approval of ...


  8. AbbVie Illustrates The Path Forward For Gilead SciencesRead the original story w/Photo

    Friday Apr 29 | Seeking Alpha

    ... is managed as a chronic illness. ABBV initial foray into the field was last year's aggressive bid to purchase Pharmacyclics this gaining a 50% stake in Imbruvica. Imbruvica was recently granted first line therapy in Chronic Lymphocytic Leukemia ...


  9. AbbVie Doubles Down on M&ARead the original story w/Photo

    Friday Apr 29 | Bloomberg

    ... to cushion the blow ahead of time. That started in a big way last year with its $21 billion purchase of Pharmacyclics, and that company's blood cancer drug Imbruvica, last spring. On Thursday, it doubled down on a high-risk, high-reward ...


  10. AbbVie (ABBV) Richard A. Gonzalez on Q1 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Thursday Apr 28 | Seeking Alpha

    ... the highest recommendation assigned by the organization. We are also approaching the one-year mark for Pharmacyclics, and we continue to be very pleased with the progress we've made to-date. The Pharmacyclics team continues to rapidly advance trial ...


  11. Bay Area biotech firms Medivation, Stemcentrx get takeover bidsRead the original story w/Photo

    Thursday Apr 28 | SFGate

    This Saturday, Jan. 24, 2015 photo shows the exterior of Abbvie, in Lake Bluff, Ill. AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall, the company announced, late Wednesday, March 4, 2015.


  12. AbbVie to Buy Cancer Drugmaker Stemcentrx for $5.8 BillionRead the original story

    Thursday Apr 28 | The Washington Post

    ... down on oncology. Last year it acquired Imbruvica, a blood cancer treatment, with its $21 billion purchase of Pharmacyclics. On April 21, it entered a deal with cancer drugmaker CytomX Therapeutics Inc. and simultaneously announced a partnership ...


  13. AbbVie acquiring cancer drug startup StemcenTrx for $5.8 billionRead the original story w/Photo

    Thursday Apr 28 | TechCrunch

    ... third acquisition for AbbVie so far as it makes moves into cancer drug research. The drug company purchased Pharmacyclics last year for $21 billion for a promising cancer drug. Stemcentrx currently has five cancer drug trials in the pipeline, with a ...


  14. AbbVie Goes Preclinical In Pursuit Of Cancer PayoffRead the original story w/Photo

    Apr 22, 2016 | Seeking Alpha

    ... into oncology. Until last year AbbVie recorded less than $1bn a year in oncology sales, but the acquisition of Pharmacyclics brought half of the economic interest of the blockbuster Imbruvica , and the approved drug Venclexta and phase III project ...


  15. 9 Things That Stand Out in Johnson & Johnson's Q1 ReportRead the original story w/Photo

    Apr 22, 2016 | The Motley Fool

    ... more than double If there was any doubt that blood cancer drug Imbruvica, which was co-developed by J&J and Pharmacyclics (now a part of AbbVie ) is going to grow into a megablockbuster, I believe this report essentially seals it. During the ...


  16. Medivation Said to Have Rebuffed Sanofi Takeover ApproachRead the original story

    Apr 13, 2016 | The Washington Post

    ... harness a patient's immune system to target tumors. Hartaj Singh, an analyst at BTIG, compared Medivation to Pharmacyclics Inc. in a note to clients on April 4. Pharmacyclics, another biotechnology company focused on cancer treatments, was acquired ...


  17. Staying Cautious On Corvus Pharma IPORead the original story w/Photo

    Mar 23, 2016 | Seeking Alpha

    ... its product candidates. Co-founder, President and CEO Richard A. Miller, M.D . was also the founder and CEO of Pharmacyclics. Prior to that, he was a co-founder, VP and director of IDEC, which later merged with Biogen. Dr. Miller received an M.D. ...


  18. AbbVie Superior Dividend Makes It A Top Choice In The Health Care SectorRead the original story w/Photo

    Mar 21, 2016 | Seeking Alpha

    ... compound in ABBV arsenal. ABBV acquired a 50% interest in the compound through the aggressive take-out of Pharmacyclics last year. The revenue generated from the product will ultimately be split with Johnson and Johnson (NYSE: JNJ ). Broad label ...


  19. Week Ahead: One Pre-Sold Biotech IPO During A Short Holiday WeekRead the original story w/Photo

    Mar 19, 2016 | The US Market Blog

    ... deal size of $115 million. The biotech is led by the executives behind blockbuster cancer drug Imbruvica at Pharmacyclics, which was sold to AbbVie (NYSE: ABBV ) for $21 billion. Developing immune checkpoint inhibitors, Corvus targets an area of ...


  20. s on the Move: Week Ending March 18Read the original story w/Photo

    Mar 18, 2016 | CFO

    ... the next CFO and treasurer at ARIAD Pharmaceuticals , succeeding Edward Fitzgerald. He formerly ran finance at Pharmacyclics. Darden Restaurants has promoted Ricardo Cardenas to head finance, taking over for Jeffrey Davis. Cardenas had been chief ...